MCK · McKesson Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $97.83B | $106.16B | $103.15B | $79.28B | $95.29B | $93.65B | $74.48B | $80.90B | $77.22B | $67.15B |
| Cost of Revenue | $94.55B | $102.47B | $99.61B | $76.13B | $92.01B | $90.40B | $71.46B | $77.75B | $74.15B | $64.13B |
| Gross Profit | $3.28B | $3.69B | $3.54B | $3.15B | $3.28B | $3.25B | $3.02B | $3.15B | $3.07B | $3.02B |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $2.20B | $2.03B | $2.07B | $2.00B | $2.03B | $2.50B | $1.87B | $2.51B | $2.09B | $1.96B |
| Total Operating Expenses | $2.24B | $2.07B | $2.13B | $2.12B | $2.06B | $2.67B | $1.92B | $2.51B | $2.12B | $1.99B |
| D&A | $157.00M | $153.00M | $163.00M | $63.00M | - | - | $64.00M | - | - | $61.00M |
| Operating Income | $1.04B | $1.62B | $1.41B | $1.03B | $1.22B | $578.00M | $1.10B | $642.00M | $951.00M | $1.04B |
| Interest Expense | $49.00M | $63.00M | $74.00M | $75.00M | $67.00M | $78.00M | $47.00M | $64.00M | $61.00M | $45.00M |
| Income Tax | $220.00M | $380.00M | $232.00M | $124.00M | $298.00M | $247.00M | $94.00M | ($18.00M) | $213.00M | $199.00M |
| Net Income | $784.00M | $1.19B | $1.11B | $915.00M | $879.00M | $241.00M | $958.00M | $589.00M | $664.00M | $768.00M |
| EPS - Basic | $6.28 | $9.63 | $8.95 | $7.04 | $6.98 | $1.88 | $7.07 | $4.45 | $4.95 | $5.32 |
| EPS - Diluted | $6.25 | $9.59 | $8.92 | $7.00 | $6.95 | $1.87 | $7.02 | $4.42 | $4.92 | $5.26 |
Balance Sheet
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.98B | $2.96B | $4.00B | $5.69B | $1.13B | $2.51B | $4.58B | $1.98B | $2.52B | $4.68B |
| Accounts Receivable | $27.98B | $28.21B | $28.29B | $25.64B | $25.83B | $25.27B | $21.62B | $23.07B | $22.49B | $19.41B |
| Inventory | $24.21B | $27.07B | $26.13B | $23.00B | $23.84B | $24.18B | $21.14B | $22.02B | $21.95B | $19.69B |
| Accounts Payable | $59.97B | $60.68B | $60.94B | $55.33B | $49.69B | $53.32B | $47.10B | $46.70B | $46.80B | $42.49B |
| Current Assets | $57.21B | $59.70B | $59.89B | $55.40B | $51.74B | $53.34B | $47.97B | $47.64B | $47.53B | $44.29B |
| Total Assets | $82.32B | $84.19B | $84.16B | $75.14B | $71.08B | $72.43B | $67.44B | $66.51B | $66.09B | $62.32B |
| Current Liabilities | $67.02B | $68.13B | $68.03B | $61.60B | $58.56B | $58.77B | $52.36B | $51.66B | $51.15B | $47.96B |
| Long-term Debt | $6.53B | $6.56B | $7.76B | $5.65B | $5.59B | $5.74B | $5.63B | $5.67B | $5.58B | $5.59B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($2.17B) | ($1.30B) | ($1.74B) | ($2.07B) | ($3.08B) | ($3.02B) | ($1.97B) | ($2.05B) | ($1.83B) | ($1.86B) |
| Retained Earnings | $22.29B | $20.71B | $19.62B | $17.92B | $16.75B | $15.96B | $14.98B | $14.27B | $13.76B | $12.29B |
Cash Flow
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($918.00M) | - | - | ($1.38B) | - | - | ($1.05B) | - | - | ($941.00M) |
| Investing Cash Flow | ($3.56B) | - | - | ($87.00M) | - | - | ($149.00M) | - | - | $39.00M |
| Financing Cash Flow | $1.18B | - | - | ($809.00M) | - | - | ($843.00M) | - | - | ($1.18B) |
| CapEx | $111.00M | - | - | $106.00M | - | - | $78.00M | - | - | $71.00M |
| Free Cash Flow | ($1.03B) | - | - | ($1.49B) | - | - | ($1.13B) | - | - | ($1.01B) |
Ratios
| Metric | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 3.4% | 3.5% | 3.4% | 4.0% | 3.4% | 3.5% | 4.1% | 3.9% | 4.0% | 4.5% |
| Operating margin | 1.1% | 1.5% | 1.4% | 1.3% | 1.3% | 0.6% | 1.5% | 0.8% | 1.2% | 1.5% |
| EBITDA margin | 1.2% | 1.7% | 1.5% | 1.4% | - | - | 1.6% | - | - | 1.6% |
| Net margin | 0.8% | 1.1% | 1.1% | 1.2% | 0.9% | 0.3% | 1.3% | 0.7% | 0.9% | 1.1% |
| Free cash flow margin | -1.1% | - | - | -1.9% | - | - | -1.5% | - | - | -1.5% |
| FCF / Net income | -1.31 | - | - | -1.62 | - | - | -1.18 | - | - | -1.32 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 2.2% | 1.9% | 2.0% | 2.5% | 2.1% | 2.7% | 2.5% | 3.1% | 2.7% | 2.9% |
| Effective tax rate | 21.9% | 24.3% | 17.3% | 11.9% | 25.3% | 50.6% | 8.9% | -3.2% | 24.3% | 20.6% |
| Return on assets | 1.0% | 1.4% | 1.3% | 1.2% | 1.2% | 0.3% | 1.4% | 0.9% | 1.0% | 1.2% |
| Return on equity | -36.1% | -91.4% | -63.8% | -44.1% | -28.5% | -8.0% | -48.6% | -28.7% | -36.3% | -41.4% |
| Return on invested capital | 18.6% | 23.3% | 19.3% | 25.3% | 36.5% | 10.6% | 27.4% | 17.7% | 19.2% | 22.0% |
| Liquidity | ||||||||||
| Current ratio | 0.85 | 0.88 | 0.88 | 0.90 | 0.88 | 0.91 | 0.92 | 0.92 | 0.93 | 0.92 |
| Quick ratio | 0.49 | 0.48 | 0.50 | 0.53 | 0.48 | 0.50 | 0.51 | 0.50 | 0.50 | 0.51 |
| Cash ratio | 0.06 | 0.04 | 0.06 | 0.09 | 0.02 | 0.04 | 0.09 | 0.04 | 0.05 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | -3.00 | -5.05 | -4.46 | -2.73 | -1.81 | -1.90 | -2.86 | -2.76 | -3.05 | -3.01 |
| Debt / Assets | 0.08 | 0.08 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | 0.08 | 0.09 |
| Debt / EBITDA | 5.47 | 3.70 | 4.94 | 5.18 | - | - | 4.84 | - | - | 5.10 |
| Interest coverage | 21.1x | 25.7x | 19.0x | 13.7x | 18.3x | 7.4x | 23.4x | 10.0x | 15.6x | 23.0x |
| Equity multiplier | -37.90 | -64.86 | -48.40 | -36.23 | -23.05 | -24.01 | -34.22 | -32.40 | -36.15 | -33.56 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 1.19 | 1.26 | 1.23 | 1.06 | 1.34 | 1.29 | 1.10 | 1.22 | 1.17 | 1.08 |
| Inventory turnover | 3.91 | 3.79 | 3.81 | 3.31 | 3.86 | 3.74 | 3.38 | 3.53 | 3.38 | 3.26 |
| Days sales outstanding | 104d | 97d | 100d | 118d | 99d | 98d | 106d | 104d | 106d | 105d |
| Days inventory outstanding | 93d | 96d | 96d | 110d | 95d | 98d | 108d | 103d | 108d | 112d |
| Days payable outstanding | 232d | 216d | 223d | 265d | 197d | 215d | 241d | 219d | 230d | 242d |
| Cash conversion cycle | -34d | -23d | -27d | -37d | -4d | -19d | -27d | -12d | -16d | -24d |
| Valuation | ||||||||||
| P / E | 138.5x | 85.5x | 86.6x | 96.1x | 82.0x | 264.4x | 76.5x | 104.7x | 88.4x | 67.7x |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 1.1x | 1.0x | 0.9x | 1.1x | 0.8x | 0.7x | 1.0x | 0.8x | 0.8x | 0.8x |
| EV / EBITDA | 93.2x | 59.3x | 63.6x | 80.5x | - | - | 63.9x | - | - | 48.2x |
| Growth | ||||||||||
| Revenue growth (YoY) | 23.4% | 11.4% | 10.1% | 6.4% | 17.8% | 21.3% | 10.9% | 14.8% | 10.1% | 7.1% |
| Revenue CAGR (3y) | 13.4% | 14.6% | 13.7% | 8.2% | 11.6% | 12.0% | 10.2% | 8.9% | 8.3% | 6.4% |
| Revenue CAGR (5y) | 11.9% | 11.1% | 11.1% | 7.3% | 10.0% | 10.2% | 7.2% | 7.6% | 7.8% | 5.6% |
| Gross profit growth (YoY) | 4.0% | 12.2% | 9.1% | 4.3% | 4.2% | 5.8% | -0.0% | -0.7% | -0.8% | -0.3% |
| Operating income growth (YoY) | 0.7% | 32.3% | 143.4% | -6.5% | 90.7% | -39.2% | 6.2% | -48.3% | -15.4% | 82.4% |
| Net income growth (YoY) | -14.3% | 34.9% | 360.6% | -4.5% | 49.2% | -63.7% | 24.7% | -45.4% | -28.3% | 58.0% |
| EPS growth (YoY) | -10.7% | 38.0% | 377.0% | -0.3% | 57.2% | -62.0% | 33.5% | -42.3% | -23.4% | 71.3% |
| EPS CAGR (3y) | 5.9% | 7.8% | 11.6% | 31.6% | - | 3.0% | 37.2% | - | 11.6% | 32.9% |
| EPS CAGR (5y) | 18.1% | - | 20.3% | 25.6% | 46.5% | - | - | 13.0% | 14.4% | 29.4% |
| FCF growth (YoY) | 30.8% | - | - | -31.5% | - | - | -11.7% | - | - | 41.0% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.7% | 57.9% | 42.4% | -5.2% | -50.2% | -65.0% | -6.1% | 16.4% | -3.5% | 18.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-31.
Business segments
$67.33B totalOncology And Multispecialty Segment$48.42B · 71.9%
Medical Surgical Solutions Segment$11.51B · 17.1%
Prescription Technology Solutions Segment$5.80B · 8.6%
North American Pharmaceutical Segment$1.60B · 2.4%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing MCKESSON CORP against the 5 most active filers in the same SIC group.
Dividends
$3.28/share trailing 12 months · +15.5% YoY
| Ex-date | Per share |
|---|---|
| Jun 1, 2026 | $0.8200 |
| Mar 2, 2026 | $0.8200 |
| Dec 1, 2025 | $0.8200 |
| Sep 2, 2025 | $0.8200 |
| Jun 2, 2025 | $0.7100 |
| Mar 3, 2025 | $0.7100 |
| Dec 2, 2024 | $0.7100 |
| Aug 30, 2024 | $0.7100 |
| Jun 3, 2024 | $0.6200 |
| Feb 29, 2024 | $0.6200 |
| Nov 30, 2023 | $0.6200 |
| Aug 31, 2023 | $0.6200 |
| May 31, 2023 | $0.5400 |
| Feb 28, 2023 | $0.5400 |
| Nov 30, 2022 | $0.5400 |
| Aug 31, 2022 | $0.5400 |
| May 31, 2022 | $0.4700 |
| Feb 28, 2022 | $0.4700 |
| Nov 30, 2021 | $0.4700 |
| Aug 31, 2021 | $0.4700 |
| May 28, 2021 | $0.4200 |
| Mar 1, 2021 | $0.4200 |
| Nov 30, 2020 | $0.4200 |
| Aug 31, 2020 | $0.4200 |